Category: 380843-75-4

On August 31, 2022, Shimazu, Yutaka; Murata, Makoto; Kondo, Takeshi; Minami, Yosuke; Tachibana, Takayoshi; Doki, Noriko; Uchida, Naoyuki; Ozawa, Yukiyasu; Yano, Shingo; Fukuda, Takahiro; Kato, Jun; Ara, Takahide; Eto, Testuya; Ishikawa, Jun; Nakamae, Hirohisa; Tanaka, Junji; Ichinohe, Tatsuo; Atsuta, Yoshiko; Nagamura-Inoue, Tokiko; the working group of the Japan Society for Transplantation and Cellular Therapy published an article.Product Details of 380843-75-4 The title of the article was The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. And the article contained the following:

The introduction of tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) treatment has dramatically improved the prognosis of CML patients and reduced the number of patients receiving allogeneic stem cell transplantation (allo-SCT). However, the impact of the newest-generation TKIs on the overall survival (OS) after allo-SCT has not been well described. To investigate the beneficial effects of TKIs on the prognosis after allo-SCT, we conducted a retrospective observational study using the Transplant Registry Unified Management Program database in Japan. We analyzed 1188 patients (male/female: 738/450; median age: 44 years; range: 16-75) who underwent their first allo-SCT between Jan. 2001 and Dec. 2018. We divided the patients into two groups according to the TKI treatment used before allo-SCT: group 1 was treated with the first generation TKI imatinib; group 2 was treated with the second generation TKIs nilotinib, dasatinib, or bosutinib and/or the third generation TKI ponatinib. We compared the post allo-SCT OS between the two groups. The 3-yr OS rates (95%CI) of groups 1 and 2 were 59.3% (54.8%-63.5%) and 65.8% (61.6%-69.6%), resp. (p = 0.017). Multivariate anal. confirmed that group 2 had superior OS after allo-SCT compared to group 1 (p = 0.002). Other factors associated with superior prognosis were age ≤65, performance status (PS) 0/1, a 6/6 HLA-matched donor and chronic-phase (CP) disease status at allo-SCT. A subgroup anal. showed poor prognoses for patients who could not obtain a mol. response before allo-SCT and patients with pos. T315I mutation in the BCR/ABL gene. In group 2, early allo-SCT was correlated with superior OS in patients with a blast-crisis disease status at allo-SCT (p = 0.001). The cumulative incidence of non-relapse mortality rate significantly decreased in group 2 (p = 0.0005). The post allo-SCT OS was improved both by pre- and post-management of allo-SCT and by the introduction of newer TKIs. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Product Details of 380843-75-4

The Article related to tyrosine kinase inhibitor allogenic stem cell transplantation myeloid leukemia, allogeneic stem cell transplantation, chronic myeloid leukemia, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Product Details of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Chiwata, Masahiko; Itonaga, Hidehiro; Sato, Shinya; Hashimoto, Miki; Fujioka, Machiko; Kasai, Sachie; Sakamoto, Hikaru; Toriyama, Eo; Nakashima, Jun; Kamijo, Rena; Kitanosono, Hideaki; Kobayashi, Yuji; Horai, Makiko; Taguchi, Masataka; Matsuo, Masatoshi; Makiyama, Junya; Takasaki, Yumi; Matsuo, Emi; Horio, Kensuke; Ando, Koji; Sawayama, Yasushi; Taguchi, Jun; Kawaguchi, Yasuhisa; Tsushima, Hideki; Imanishi, Daisuke; Imaizumi, Yoshitaka; Yoshida, Shinichiro; Jo, Tatsuro; Nonaka, Hiroaki; Moriuchi, Yukiyoshi; Nagai, Kazuhiro; Yokota, Ken-ichi; Hata, Tomoko; Miyazaki, Yasushi published an article in 2021, the title of the article was Efficacy and cardiovascular adverse events of long-term treatment with tyrosine kinase inhibitors for chronic myeloid leukemia: a report from the Nagasaki CML study group.Category: piperazines And the article contains the following content:

The standard treatment for chronic myeloid leukemia (CML) is the continuous use of tyrosine kinase inhibitors (TKIs), which results in a favorable prognosis for the majority of patients. Recent studies have identified cardiovascular diseases (CVDs) as late adverse events (AEs) related to TKIs. In this study, we evaluated the long-term efficacy and AEs of TKIs, focusing on CVDs. We performed a retrospective survey of CML patients (diagnosed from 2001 to 2016) treated with TKIs in Nagasaki Prefecture. Clin. data were obtained from their medical records. We analyzed the survival, estimated cumulative incidence of CVDs, and risk factors for CVD among CML patients treated with TKIs. The overall survival rate of 264 CML patients treated with TKIs (median age 58 years old) was 89.6% [95% confidence interval (CI), 84.9-92.9%], and 80.5% (95% CI, 73.4-85.9%) at 5 and 10 years after the CML diagnosis, resp. CVD events occurred in 26 patients (9.8%, median age 67.5 years old) with a median 65.5 mo of TKI treatment. The cumulative incidences at 2 and 5 years was 2.4% (95% CI, 1.0-4.8%) and 5.2% (95% CI, 2.8-8.6%), resp. Hypertension and a high SCORE chart risk at the diagnosis of CML were associated with CVD events during TKI treatment. TKI treatment contributed to the long-term survival of CML patients in Nagasaki Prefecture in a “real-world” setting, but the incidence of CVDs seemed to be increased in these patients. A proper approach to managing risk factors for CVD is warranted to reduce CVD events during TKI treatment. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Category: piperazines

The Article related to cardiovascular adverse event tki treatment efficacy chronic myeloid leukemia, adverse event, cardiovascular disease, chronic myeloid leukemia, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Category: piperazines

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Yue, Xiaomeng; Hincapie, Ana L.; Li, Yuxiang; Guo, Jeff J. published an article in 2022, the title of the article was Safety and cost-effectiveness of ponatinib versus other tyrosine kinase inhibitors as second-line therapy in patients with chronic myeloid leukemia in the United States.Computed Properties of 380843-75-4 And the article contains the following content:

To evaluate the cost-effectiveness of ponatinib compared with second-line TKIs in the treatment of adult patients with CML who failed, or were intolerant to, first-line TKIs. A Markov state transition model was conducted. Model transition, adverse-effect probabilities, utility data and medical costs were obtained from clin. trials and literature. Measurements included medications, follow-ups, adverse events, allogeneic stem cell transplantation and quality-adjusted life years (QALYs). Univariable and Bayesian multivariable probabilistic sensitivity analyses were conducted using Monte Carlo simulations. Dasatinib resulted in an ICER of $79,086/QALY compared to nilotinib. Ponatinib yielded an ICER of $176,278/QALY and $141,563/QALY compared to dasatinib and nilotinib, resp. Dasatinib was the optimal treatment at a $100,000/QALY threshold. The probability (36%-40%) for ponatinib or dasatinib optimal treatment was associated with thresholds of $160,000-$180,000/QALY. Dasatinib and ponatinib can be considered cost-effective options and provide clin. benefits compared to other second-line TKIs for CML in the US. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Computed Properties of 380843-75-4

The Article related to ponatinib dasatinib anticancer agent economic evaluation chronic myeloid leukemia, treatment outcome, bosutinib, dasatinib, nilotinib, stem cell transplant, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Computed Properties of 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 31, 2022, Nakajima, Rui; Matsuo, Takuji; Sumiyoshi, Ritsu; Saito, Sumiko; Yamamoto, Tadashi; Matsumoto, Kensuke; Akiyama, Nobu; Ooi, Jun; Ota, Yasunori; Shirafuji, Naoki; Tashiro, Haruko published an article.Application In Synthesis of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was Extramedullary blast crisis in a chronic myeloid leukaemia patient after achieving a major molecular response with bosutinib. And the article contained the following:

FIrst report of an extramedullary blast crisis in the lymph nodes of a chronic myeloid leukemia (CML) patient on bosutinib. A 78-yr-old man was diagnosed with chronic phase (CP) CML in March 2015 and was treated with dasatinib 100 mg once daily as a first-line therapy. An excisional lymph node biopsy revealed the proliferation of blast cells with a starry-sky appearance. Bone marrow anal. did not indicate an increase in abnormal cells, and FISH anal. showed an absence of BCR-ABL1 fusion genes. From these findings, the patient was diagnosed with extramedullary B-lymphoid blast crisis that occurred in CP CML while under MMR. This case demonstrates the need to be mindful of the possibility of extramedullary disease even in patients having achieved MMR following TKI therapy. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Application In Synthesis of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to bosutinib antitumor chronic myeloid leukemia extramedullary blast crisis, cml, bosutinib, extramedullary, ponatinib, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Application In Synthesis of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Zhang, Lishun; Yang, Zichao; Sang, Huiting; Jiang, Ying; Zhou, Mingfeng; Huang, Chuan; Huang, Chunhui; Wu, Xiaoyun; Zhang, Tingting; Zhang, Xingmei; Wan, Shanhe; Zhang, Jiajie published an article in 2021, the title of the article was Identification of imidazo[4,5-c]pyridin-2-one derivatives as novel Src family kinase inhibitors against glioblastoma.Recommanded Product: 380843-75-4 And the article contains the following content:

Glioblastoma multiforme (GBM) is the most common and malignant primary brain tumor in the central nervous system (CNS). As the ideal targets for GBM treatment, Src family kinases (SFKs) have attracted much attention. Herein, a new series of imidazo[4,5-c]pyridin-2-one derivatives were designed and synthesized as SFK inhibitors. Compounds , , , exhibited potential Src and Fyn kinase inhibition in the submicromolar range, of which were next tested for their antiproliferative potency on four GBM cell lines. Compound showed effective activity against U87, U251, T98G, and U87-EGFRvIII GBM cell lines, comparable to that of lead compound PP2. Mol. dynamics (MDs) simulation revealed the possible binding patterns of the most active compound in ATP binding site of SFKs. ADME prediction suggested that accord with the criteria of CNS drugs. These results led us to identify a novel SFK inhibitor as candidate for GBM treatment. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 380843-75-4

The Article related to dasatinib anticancer agent glioblastoma, glioblastoma, src family kinase, imidazo[4,5-c]pyridin-2-one, kinase inhibitor, molecular simulation, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Recommanded Product: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On July 31, 2022, Claudiani, Simone; Janssen, Jeroen J. W. M.; Byrne, Jenny; Smith, Graeme; Blijlevens, Nicole; Raghavan, Manoj; Smith, Matthew; Clark, Richard E.; Mclain-Smith, Susan; Carter, Angela M.; Milojkovic, Dragana; Apperley, Jane F. published an article.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was A retrospective observational research study to describe the real-world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands. And the article contained the following:

To describe the real-world effectiveness and safety of bosutinib in patients with chronic myeloid leukemia (CML). This was a multi-center, retrospective, non-interventional chart review study conducted in 10 hospitals in the United Kingdom and the Netherlands. Eighty-seven patients were included. Bosutinib was the third-line tyrosine kinase inhibitor (TKI) in 33 (38%) and fourth-line in 44 (51%) patients. Median treatment duration was 15.6 mo. Among 84 patients in chronic phase (CP) at baseline, 26 (31%) switched to bosutinib due to resistance and 57 (68%) due to intolerance to prior TKIs. Cumulative complete cytogenetic and major mol. response rates in CP patients were 67% and 55%, resp. After a median follow-up of 21.5 mo, nine (11%) patients in CP died; estimated overall survival rates at 1 and 2 years postbosutinib initiation were 95% and 91%, resp. Overall, 33/87 (38%) patients discontinued bosutinib due to either lack of efficacy/disease progression (17%), adverse events (14%), death (2%), or other reasons (5%). Eighty-two (94%) patients experienced ≥1 adverse event possibly related to bosutinib, most commonly diarrhea (52%). Bosutinib used in routine clin. practice in heavily pretreated patients with CML is an effective treatment for patients in CP and is generally tolerable. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to bosutinib anticancer agent chronic myeloid leukemia, bosutinib, chronic myeloid leukemia, retrospective studies, tyrosine kinase inhibitor, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Quality Control of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On December 31, 2020, G. Lindstroem, H. Jonathan; Friedman, Ran published an article.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile The title of the article was The effects of combination treatments on drug resistance in chronic myeloid leukaemia: an evaluation of the tyrosine kinase inhibitors axitinib and asciminib. And the article contained the following:

Abstract: Background: Chronic myeloid leukemia is in principle a treatable malignancy but drug resistance is lowering survival. Recent drug discoveries have opened up new options for drug combinations, which is a concept used in other areas for preventing drug resistance. Two of these are (I) Axitinib, which inhibits the T315I mutation of BCR-ABL1, a main source of drug resistance, and (II) Asciminib, which has been developed as an allosteric BCR-ABL1 inhibitor, targeting an entirely different binding site, and as such does not compete for binding with other drugs. These drugs offer new treatment options. Methods: We measured the proliferation of KCL-22 cells exposed to imatinib-dasatinib, imatinib-asciminib and dasatinib-asciminib combinations and calculated combination index graphs for each case. Moreover, using the median-effect equation we calculated how much axitinib can reduce the growth advantage of T315I mutant clones in combination with available drugs. In addition, we calculated how much the total drug burden could be reduced by combinations using asciminib and other drugs, and evaluated which mutations such combinations might be sensitive to. Results: Asciminib had synergistic interactions with imatinib or dasatinib in KCL-22 cells at high degrees of inhibition. Interestingly, some antagonism between asciminib and the other drugs was present at lower degrees on inhibition. Simulations revealed that asciminib may allow for dose reductions, and its complementary resistance profile could reduce the risk of mutation based resistance. Axitinib, however, had only a minor effect on T315I growth advantage. Conclusions: Given how asciminib combinations were synergistic in vitro, our modeling suggests that drug combinations involving asciminib should allow for lower total drug doses, and may result in a reduced spectrum of observed resistance mutations. On the other hand, a combination involving axitinib was not shown to be useful in countering drug resistance. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to axitinib asciminib antitumor tyrosine kinase inhibitor chronic myeloid leukemia, allosteric inhibitor, drug combination, targeted therapy, Pharmacology: Effects Of Neoplasm Inhibitors and Cytotoxic Agents and other aspects.Reference of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

Mulas, Olga; Caocci, Giovanni; Mola, Brunella; La Nasa, Giorgio published an article in 2021, the title of the article was Arterial hypertension and tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and meta-analysis.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile And the article contains the following content:

Off-target effects in chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKIs) are associated with cardiovascular toxicity. Hypertension represents an important cardiovascular complication and, if not appropriately managed, can contribute to developing thrombotic events. Third-generation TKI ponatinib is associated with hypertension development, and its use is more restricted than in the past. Few data are reported for second-generation TKI, nilotinib, dasatinib, and bosutinib. The aim of this article was to evaluate with a systematic review and meta-anal. the real incidence of hypertension in CML patients treated with second- or third-generation TKI. The PubMed database, Web of Science, Scopus, and ClinicalTrials.gov were systematically searched for studies published between Jan. 1, 2000, and Jan. 30, 2021; the following terms were entered in the database queries: Cardiovascular, Chronic Myeloid Leukemia, CML, Tyrosine kinases inhibitor, TKI, and Hypertension. The study was carried out according to the Preferred Reporting Items for Systematic and Meta-Analyses (PRISMA) statement. A pooled anal. of hypertension incidence was 10% for all new-generation TKI, with an even higher prevalence with ponatinib (17%). The comparison with the first-generation imatinib confirmed that nilotinib was associated with a significantly increased risk of hypertension (RR 2; 95% CI; 1.39-2.88, I2 = 0%, z = 3.73, p = 0.0002). The greatest risk was found with ponatinib (RR 9.21; 95% CI; 2.86-29.66, z = 3.72, p = 0.0002). Hypertension is a common cardiovascular complication in CML patients treated with second- or third-generation TKI. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

The Article related to arterial hypertension tyrosine kinase inhibitor chronic myeloid leukemia metaanalysis, cardiovascular, chronic myeloid, hypertension, leukemia, tyrosine kinase inhibitor, Pharmacology: Other (All Agents and Effects Not Otherwise Assignable) and other aspects.Recommanded Product: 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On August 31, 2020, Petzer, Andreas L.; Sperr, Wolfgang R.; Buxhofer-Ausch, Veronika; Sliwa, Thamer; Schmidt, Stefan; Greil, Richard; Woelfler, Albert; Pichler, Petra; Dormann, Clemens; Burgstaller, Sonja; Tinchon, Christoph; Lang, Alois; Goebel, Florian; Uthman, Shanow; Muenchmeier, Niklas; Valent, Peter published an article.COA of Formula: C26H29Cl2N5O3 The title of the article was A multicenter retrospective evaluation of Chronic Myeloid Leukemia (CML) therapy in Austria assessing the impact of early treatment response on patient outcomes in a real-life setting – R-Effect study. And the article contained the following:

Methods: The Retrospective Evaluation of Early response in CML for long-term Treatment outcome (R-Effect), a multicenter, retrospective chart review, documented patients with newly diagnosed CML-CP starting first-line TKI therapy in routine clin. practice. The primary aim was to assess the 5-yr overall survival rate. Results: Of the 211 patients from 12 centers across Austria (Jan. 2004-May 2010), 176 (median age, 56 years) were included in the anal. All patients received first-line therapy with imatinib. Overall, 136 patients (77.3%) achieved ETR (ETR+ group), whereas 40 (22.7%) did not reach ETR (ETR- group). The ETR+ group had higher 5-yr overall survival (92.5% vs. 77.5%, P = 0.018) and progression-free survival (95.6% vs. 87.5%, P = 0.06) rates compared with the ETR- group. As expected, more patients in the ETR- group were switched to another TKI. At the last contact, 120 patients were still on imatinib and 44 had switched to another TKI (25 to nilotinib, 15 to dasatinib, and 4 to bosutinib). Conclusion: The data are in line with randomized trials demonstrating that ETR is associated with improved survival and thus confirmed these results in patients treated in daily clin. routine. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).COA of Formula: C26H29Cl2N5O3

The Article related to chronic myeloid leukemia therapy, chronic myeloiud leukemia, chronic phase, clinical routine, retrospective evaluation, tyrosine kinase inhibitors, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.COA of Formula: C26H29Cl2N5O3

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics

On January 31, 2022, Balboa Ramilo, Amanda; Becirovic-Agic, Mediha; Petri, Marcelo Heron; Mani, Kevin; Wanhainen, Anders; Waagsaeter, Dick published an article.SDS of cas: 380843-75-4 The title of the article was The tyrosine kinase inhibitor Bosutinib does not inhibit angiotensin II-induced abdominal aortic aneurysm: Validation of the importance of PDGFR and c-Kit tyrosine kinases by Imatinib. And the article contained the following:

Validation of the importance of PDGFR and c-Kit tyrosine kinases by imatinib. All experiments were approved by the Animal Experiments Ethical Committee in Uppsala. Mice were divided into four groups. One group of control mice (n =8) was infused with Ringer’s solution In the other three groups, aneurysm was induced by infusion of 1000 ng/kg/min of AngII. AngII-infused animals were treated with vehicle (n = 20), 10 mg/kg of Bosutinib (Bos, Cat.number S1014, Selleckchem, TX, USA) (n = 20) or 100 mg/kg of Bosutinib (n = 10) by oral gavage, for 22 days. Control animals also received vehicle by oral gavage. On the last day of the experiment, an abdominal ultrasound (Vevo 1100 ultrasound, VisualSonics) was performed for measurement of aortic diameter Control animals had an average aortic diameter of 1.2 ± 0.108 mm. Aneurysm was defned as an aortic diameter equal or superior to 1.8 mm (1.5-fold increase relative to control). These results indicate that treatment of AngII-induced mice with Bosutinib, in a similar dose to Imatinib or higher, does not have an effect on AAA development. This confirms that inhibition of the PDGFR and/or c-Kit is necessary for the effect of Imatinib on abdominal aortic aneurysm development. Thus, drugs inhibiting c-Kit and PDGFR should be of more interest to test in the context of abdominal aortic aneurysm. The experimental process involved the reaction of 4-((2,4-Dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methylpiperazin-1-yl)propoxy)quinoline-3-carbonitrile(cas: 380843-75-4).SDS of cas: 380843-75-4

The Article related to abdominal aortic aneurysm pdgfr ckit tyrosine kinase imatinib, aneurysm, inhibitor, rupture, tyrosine kinase, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.SDS of cas: 380843-75-4

Referemce:
Piperazine – Wikipedia,
Piperazines – an overview | ScienceDirect Topics